These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 36980287)

  • 41.
    Tarantini F; Cumbo C; Zagaria A; Parciante E; Anelli L; Coccaro N; Tota G; Minervini CF; Redavid I; Rossi AR; Conserva MR; Specchia G; Musto P; Albano F
    Hematology; 2022 Dec; 27(1):842-846. PubMed ID: 35938951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
    Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutations in myeloproliferative neoplasms - their significance and clinical use.
    Schischlik F; Kralovics R
    Expert Rev Hematol; 2017 Nov; 10(11):961-973. PubMed ID: 28914569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Ferreira Cristina S; Polo B; Lacerda JF
    Semin Hematol; 2018 Oct; 55(4):215-222. PubMed ID: 30502850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biology and Current Treatment of Myeloproliferative Neoplasms.
    Ali H; Pullarkat V; Snyder D
    Cancer Treat Res; 2021; 181():151-165. PubMed ID: 34626360
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
    Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO
    Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
    Yue Y; Wei W; Guo Y; Wang F; Dong W; Liu Y; Lin Y; Cao Y; Gu W
    Am J Case Rep; 2020 Oct; 21():e925151. PubMed ID: 33021971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
    Berzoti-Coelho MG; Ferreira AF; de Souza Nunes N; Pinto MT; Júnior MC; Simões BP; Martínez-A C; Souto EX; Panepucci RA; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Current Understanding of Myeloproliferative Neoplasm-Related Gene Mutations and Cytokine -Review].
    He ZP; Wu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):589-594. PubMed ID: 29665937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment.
    Tefferi A; Barbui T
    Mayo Clin Proc; 2005 Sep; 80(9):1220-32. PubMed ID: 16178503
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
    Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
    Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Mroczkowska-Bękarciak A; Wróbel T
    Front Genet; 2023; 14():1241912. PubMed ID: 37745842
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.
    Mullally A
    Pathologe; 2016 Nov; 37(Suppl 2):175-179. PubMed ID: 27796499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in understanding and management of myeloproliferative neoplasms.
    Vannucchi AM; Guglielmelli P; Tefferi A
    CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular diagnostics of myeloproliferative neoplasms.
    Langabeer SE; Andrikovics H; Asp J; Bellosillo B; Carillo S; Haslam K; Kjaer L; Lippert E; Mansier O; Oppliger Leibundgut E; Percy MJ; Porret N; Palmqvist L; Schwarz J; McMullin MF; Schnittger S; Pallisgaard N; Hermouet S;
    Eur J Haematol; 2015 Oct; 95(4):270-9. PubMed ID: 25951317
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.
    De Roeck L; Michaux L; Debackere K; Lierman E; Vandenberghe P; Devos T
    Hematology; 2018 Dec; 23(10):785-792. PubMed ID: 29993347
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Zeeh FC; Meyer SC
    Hamostaseologie; 2021 Jun; 41(3):197-205. PubMed ID: 34192778
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.
    Zhao Y; Reddi D; McCracken J; Iranzad N; Rehder C; Neff J; Wang E
    Arch Pathol Lab Med; 2022 Jun; 146(6):710-717. PubMed ID: 34506622
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case of double positive myeloproliferative neoplasm: A diagnostic and therapeutic challenge.
    Shaikh AB; Aribandi A; Gupta A; Subramanian SK; Goyal M
    Indian J Pathol Microbiol; 2021; 64(4):820-823. PubMed ID: 34673614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.